Treat-to-Target in RA Hits the Bull’s-eye
Recent findings allay concerns about increased costs and rates of adverse events related to TTT strategies.
Reference1. Solomon DH, Yu Z, Katz JN, et al. Adverse events and resource use before and after treat to target in rheumatoid arthritis: a post-hoc analysis of a randomized controlled trial. Arthritis Care Res. 2018 Sep 17. doi: 10.1002/acr.23755. [Epub ahead of print]
Solomon and colleagues from multiple centers looked at rates of adverse events, office visits, and diagnostic utilization before, during, and after implantation of the treat-to-target (TTT) initiative for rheumatoid arthritis (RA) and found no significant difference before or after.1 Thumb through the slides for the details of their study and the take-home points for clinicians.
DMARD, disease-modifying antirheumatic drug.
RA, rheumatoid arthritis.
